Literature DB >> 18677966

Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.

Theodor H Lippert1, Hans-Jörg Ruoff, Manfred Volm.   

Abstract

Drug resistance is the major reason for failure in cancer chemotherapy. Resistance may be either pre-existent (intrinsic resistance), or induced by drugs (acquired resistance), So far, no strategy has been found to overcome resistance, which is based on highly complex and individually variable biological mechanisms. In present clinical practice, drug resistance can only be recognized during treatment, after long lag times. Thus diagnostic tests are re quired, indicating resistance at an earlier stage, in order to avoid unnecessary medication, frequently associated with toxic side-effects. A number of new anti-cancer drugs are now available. In contrast to the unspecifically acting cytostatic chemotherapy, these compounds have targeted actions. However, as recent studies have shown, resistances and severe side-effects can also be found with targeted drugs. With the increasing number of new treatment regimens, the early diagnosis of resistance will optimize therapy, and indeed will be indispensable for individual cancer therapy. The resistance assays available for use in clinical practice should be integrated into cancer therapy. Research into this neglected area needs to be intensified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677966     DOI: 10.1055/s-0031-1296504

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  57 in total

1.  Resistance tests were not mentioned.

Authors:  Theodor H Lippert
Journal:  Dtsch Arztebl Int       Date:  2010-06-04       Impact factor: 5.594

Review 2.  MicroRNAs: master regulators of drug resistance, stemness, and metastasis.

Authors:  Umar Raza; Jitao David Zhang; Ozgür Sahin
Journal:  J Mol Med (Berl)       Date:  2014-02-09       Impact factor: 4.599

3.  Reaction of carbon monoxide with cystathionine β-synthase: implications on drug efficacies in cancer chemotherapy.

Authors:  Brian Kawahara; Suvajit Sen; Pradip K Mascharak
Journal:  Future Med Chem       Date:  2020-02-07       Impact factor: 3.808

Review 4.  F-box proteins involved in cancer-associated drug resistance.

Authors:  Jian Gong; Yuqian Zhou; Deliang Liu; Jirong Huo
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

5.  A stapled POL κ peptide targets REV1 to inhibit mutagenic translesion synthesis.

Authors:  Nimrat Chatterjee; Sanjay D'Souza; Mohammad Shabab; Cynthia A Harris; Gerard J Hilinski; Gregory L Verdine; Graham C Walker
Journal:  Environ Mol Mutagen       Date:  2020-07-01       Impact factor: 3.216

Review 6.  Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy.

Authors:  Sachin Kumar Deshmukh; Sanjeev Kumar Srivastava; Teja Poosarla; Donna Lynn Dyess; Nicolette Paolaungthong Holliday; Ajay Pratap Singh; Seema Singh
Journal:  Ann Transl Med       Date:  2019-10

Review 7.  Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.

Authors:  Benjamin Bonavida
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

8.  miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.

Authors:  Wei Zhu; DanXia Zhu; Shiqiang Lu; Tongshan Wang; Jian Wang; Binghua Jiang; Yongqian Shu; Ping Liu
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

9.  Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells.

Authors:  Xue-mei Wu; Xiang-qiang Shao; Xian-xin Meng; Xiao-na Zhang; Li Zhu; Shi-xu Liu; Jian Lin; Hua-sheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

10.  miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy.

Authors:  Xinming Du; Bing Liu; Xuerong Luan; Qing Cui; Leping Li
Journal:  Exp Ther Med       Date:  2017-10-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.